Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the effect of various tobacco products (including but not limited to combustible cigarettes, medicinal nicotine, electronic cigarettes, and smokeless tobacco) on cutaneous wound healing. There will also be a non- smoking control group. This study will be designed as a pilot study. The majority of individuals will be recruited from ongoing studies at the University of Minnesota - Tobacco Research Programs.
Participants will be recruited from ongoing studies will some recruitment of tobacco users and non-smoking controls outside of ongoing studies. In this prospective, cohort study of various tobacco users and non-smokers, a punch biopsy model of wound healing will be used to determine the effects of various tobacco products on inflammatory response and oxidative stress response to wounding:
Clinical wound inflammation as assessed by:
Biological wound inflammation as assessed by:
Systemic inflammation as assessed by:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tobacco Users | Participants in this group use some form of tobacco. | ||
| Non-Tobacco Users | Participants in this group do not use tobacco products. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Cutaneous temperature | Cutaneous temperature is measured using in infrared thermographic camera (FLIR T460 Infrared Thermal Imaging Camera, FLIR Systems, Inc., Wilsonville, OR). Images will be analyzed using a camera-specific software (FLIR Tools) that interrogates cutaneous temperature points of the image. The units are software-determined, arbitrary units that are standardized within the FLIR imaging system but do not correspond to standard units of measure. | approximately 7 days |
| Cutaneous perfusion | Cutaneous perfusion is measured using Laser Doppler Technologies (PeriFlux 6000, Perimed AB, Stockholm, Sweden). Tissue oxygenation is measured in the capillaries only. Perfusion is measured in arbitrary system defined "perfusion units." | approximately 7 days |
| Cutaneous oxygenation | Cutaneous oxygenation is measured using Laser Doppler Technologies (PeriFlux 6000, Perimed AB, Stockholm, Sweden). Tissue oxygenation is measured in the capillaries only. Oxygenation is measured in mmHg. | approximately 7 days |
| Immunohistochemistry - markers of inflammation | CD31 and C68 are stained via standard immunohistochemistry methods on punch biopsied specimens. Unit of measure is cell count. | approximately 7 days |
| Biological Wound Inflammation | IL-1b, 6 and 10 are measured using standard immunoassays and reported in units of pg/ml. These cytokines will be measured in both the skin and blood. | approximately 7 days |
| Tumor necrosis factor (TNF)-alpha | TNF-alpha is measured using standard immunoassays and reported in units of pg/ml. This cytokine will be measured in both the skin and blood. |
Not provided
Not provided
For participants NOT enrolled in an active Tobacco Research Programs study:
Inclusion criteria:
The remaining inclusion criteria is different depending on the type of tobacco product the individual uses:
A) Non Smokers
B) E-Cigarette Users
C) Medicinal Nicotine Users
D) Smokeless Tobacco Users
- Have not smoked cigarettes in the last month
- Has at least 5 instances of using smokeless tobacco per day for a minimum of 4 days per week
E) Combustible Tobacco and E-Cigarette Dual Users
F) Combustible Tobacco and Medicinal Nicotine Dual Users
Exclusion Criteria:
For participants enrolled in an active Tobacco Research Programs study:
Inclusion Criteria:
Concurrent enrollment in one of the following studies (if the study is registered with clinicaltrials.gov, please click the link to see inclusion/exclusion criteria):
A) Impact of Very Low Nicotine Content Cigarettes in a Complex Marketplace - https://clinicaltrials.gov/ct2/show/NCT03272685 B) Clinical trial to assess the removal of filter ventilation on smoking behavior and biomarkers - https://clinicaltrials.gov/ct2/show/NCT03637972 C) e-Cigarettes: Formaldehyde DNA Adducts, Oxidative Damage, and Potential Toxicity and Carcinogenesis - https://clinicaltrials.gov/ct2/show/NCT03284632 D) Methodology and Development of Tobacco Related Biomarkers, part of "Metabolism of Carcinogenic Tobacco-Specific Nitrosamines" Inclusion Criteria - Generally good physical and mental health as evidenced by a medical history with no unstable medical conditions and study physician approval.
Exclusion Criteria
- Pregnant or breastfeeding or plans to become pregnant
SMOKERS
Inclusion:
- Currently smoking at least 10 cigarettes per day;
- History of at least 5 years smoking;
- Stable smoking pattern for the past 1 year (<50% change in brand or number of cigarettes smoked).
FORMER SMOKERS
Inclusion:
NEVER SMOKERS
Exclusion:
- Smoking more than 100 cigarettes in their lifetime
NICOTINE REPLACEMENT USERS
- Inclusion/Exclusion dependent on intended sample use
E-CIGARETTE USERS (Addendum study) - Inclusion/Exclusion dependent on intended sample use
SMOKELESS TOBACCO USERS (Addendum study)
- Inclusion/Exclusion dependent on intended sample use
E) Clinical Trial of Watercress in Detoxification of Environmental Toxicants and Carcinogens - https://clinicaltrials.gov/ct2/show/NCT03978117 F) Metabolism of Deuterated NNN in Smokeless Tobacco Users - https://clinicaltrials.gov/ct2/show/NCT02414477 G) Biomarkers of Exposure and Effect in SREC Users - https://clinicaltrials.gov/ct2/show/NCT04003805 H) Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure - https://www.clinicaltrials.gov/ct2/show/NCT03998735 I) Phase 1 Trial of Indole-3-Carbinol and Silibinin Inclusion Criteria
- Current smoker of ≥ 8 cigarettes per day for at least the last 6 months by self-report
Adequate blood counts, and adequate liver and kidney function defined as follows:
Hemoglobin ≥ 9 g/dL for women, ≥ 10 g/dL for men
Platelet count ≥ 100 x 109/L
Total bilirubin ≤ Institutional upper limit of normal (≤ 1.3 mg/dL for UMMC)
ALT ≤ 1.5 times institutional upper limit of normal
Creatinine ≤ 1.4 g/dL and estimated GFR ≥ 80 mL/min/1.7m2
Exclusion Criteria
- Daily proton pump inhibitor, H2-blocker (i.e., ranitidine, famotidine), and/or calcium carbonate use
- History of gastric bypass surgery, gastric banding, bowel resection, malabsorption syndromes such as celiac sprue or pancreatic insufficiency, or other conditions that may affect gastric or intestinal absorption of nutrients
- Use of tobacco products other than cigarettes (i.e. snuff, snuz, smokeless tobacco, cigars, pipes), within 7 days of study registration
Exclusion Criteria:
- Any tattoos on the medial upper arm (note that one medial upper arm can have a tattoo, but at least one side does not have a tattoo).
- History of delayed wound healing.
Not provided
Not provided
Not provided
Participants must be enrolled in an ongoing study for participation in this sub-study or meet the inclusion/exclusion criteria for participants not enrolled in an active study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Dorothy Hatsukami, PhD | University of Minnesota | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Minnesota | Minneapolis | Minnesota | 55455 | United States |
Not provided
| ID | Term |
|---|---|
| D012907 | Smoking |
| D064424 | Tobacco Use |
| D000073869 | Tobacco Smoking |
| ID | Term |
|---|---|
| D001519 | Behavior |
Not provided
Not provided
Not provided
Not provided
Not provided
A separate electronic consent form will be used to allow the use of specimens collected (both blood and tissue) for genetic research. Participants can decline the use of their specimens for genetic research but may not be able to participate in the study. The study coordinator will keep a log through REDCap of which participants declined the use of their samples for genetic research to ensure those samples will not be used for genetic research. Participants will also have the option to allow the future use of their de-identified specimens collected for general research, including genetic purposes.
| approximately 7 days |